scholarly journals Regulation of EphB2 activation and cell repulsion by feedback control of the MAPK pathway

2008 ◽  
Vol 183 (5) ◽  
pp. 933-947 ◽  
Author(s):  
Alexei Poliakov ◽  
Maria L. Cotrina ◽  
Andrea Pasini ◽  
David G. Wilkinson
Keyword(s):  
Feedback Loop ◽  
Fibroblast Growth Factor Receptor ◽  
Mapk Pathway ◽  
Tyrosine Phosphatase ◽  
Growth Factor Receptor ◽  
Mitogen Activated Protein Kinase ◽  
Eph Receptor ◽  
Mitogen Activated Protein ◽  
Mediate Cell ◽  
Cell Repulsion

In this study, we investigated whether the ability of Eph receptor signaling to mediate cell repulsion is antagonized by fibroblast growth factor receptor (FGFR) activation that can promote cell invasion. We find that activation of FGFR1 in EphB2-expressing cells prevents segregation, repulsion, and collapse responses to ephrinB1 ligand. FGFR1 activation leads to increased phosphorylation of unstimulated EphB2, which we show is caused by down-regulation of the leukocyte common antigen–related tyrosine phosphatase receptor that dephosphorylates EphB2. In addition, FGFR1 signaling inhibits further phosphorylation of EphB2 upon stimulation with ephrinB1, and we show that this involves a requirement for the mitogen-activated protein kinase (MAPK) pathway. In the absence of activated FGFR1, EphB2 activates the MAPK pathway, which in turn promotes EphB2 activation in a positive feedback loop. However, after FGFR1 activation, the induction of Sprouty genes inhibits the MAPK pathway downstream of EphB2 and decreases cell repulsion and segregation. These findings reveal a novel feedback loop that promotes EphB2 activation and cell repulsion that is blocked by transcriptional targets of FGFR1.

scholarly journals Decreased Phosphorylated ERK 1/2 in Individuals with Autism

2019 ◽  
Author(s):  
Anthony Russo ◽  
Albert Mensah ◽  
Judith Bowman
Keyword(s):  
Intracellular Signaling ◽  
Mapk Pathway ◽  
Growth Factor Receptor ◽  
Autism Spectrum ◽  
Mitogen Activated Protein Kinase ◽  
Signaling Cascades ◽  
Extracellular Signal ◽  
Mitogen Activated Protein ◽  
Epidermal Growth ◽  
Spectrum Disorders

Autism spectrum disorders (ASDs) are complex, highly heritable neurodevelopmental disorders affecting ∼1 in 60-100 children. The extracellular signal-regulated kinases, ERK1 and ERK2, are central elements of one of the most prominent intracellular signaling cascades, the mitogen activated protein kinase (MAPK) pathway. They are genetically linked to ASDs and other syndromes typified by intellectual disability. In this study, we measured the concentration of phosphorylated (activated) ERK 1 and 2. We present evidence that ERK is decreased in individuals with autism, and that ERK levels are associated with decreased Epidermal Growth Factor Receptor (EGFR).

scholarly journals Proliferation of Peripheral Blood-derived Endothelial Progenitor Cells from Stable Angina Subjects

2014 ◽  
Vol 6 (2) ◽  
pp. 91 ◽  
Author(s):  
Yudi Her Oktaviono ◽  
Djanggan Sargowo ◽  
Mohammad Aris Widodo ◽  
Yanni Dirgantara ◽  
Angliana Chouw ◽  
...  
Keyword(s):  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Stable Angina ◽  
Peripheral Blood ◽  
Mapk Pathway ◽  
Growth Factor Receptor ◽  
Mapk Signaling ◽  
Mitogen Activated Protein Kinase ◽  
Endothelial Progenitor ◽  
Mitogen Activated Protein

BACKGROUND: A population of circulating Endothelial Progenitor Cells (EPCs) has been reported to play important role in maintaining endothelial function and integrity. Since EPCs culture is crucial and an optimized medium is currently available. Therefore we conducted a study to investigate whether stable angina subjects peripheral blood-derived EPCs could be cultured in this medium. Here, we performed study to detect EPCs characteristics and extracellular signalregulated kinase (Erk)1/2 Mitogen-Activated Protein Kinase (MAPK) pathway as possible underlying pathway for EPCs proliferation.METHODS: Peripheral blood EPCs from 8 stable angina subjects were cultured in an optimized medium with/without addition of supplement for 1 or 3 days. Then, the membrane of cultured EPCs were detected with immunofluorescence method for CD34, Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) and CD133. Colony forming unit (CFU) enumeration was performed. XTT Cell proliferation assay was performed to assess EPCs growth after 1 and 3-days culture. The western blot analysis was performed to detect possible activation of Erk1/2 MAPK.RESULTS: Number of EPCs and CFU cultured for 3 days were significantly higher than the ones cultured for 1 day (p=0.012). EPCs membrane markers from stable angina subjects were detected as well as CFUs were formed. There were significant increase of EPCs number, CFUs number and phosphorylated-Erk2 amount when the groups with and without supplement were compared (p<0.05). Meanwhile U0126, a MAPK Erk1/2 (MEK1/2) inhibitor, significantly inhibited the supplement-induced EPCs number, CFUs number and phosphorylated-Erk2 amount (p<0.05).CONCLUSION: Our results showed that ERK2 MAPK signaling pathway might play an important role in supplement-induced peripheral blood EPCs proliferation in subjects with stable angina.KEYWORDS: endothelial progenitor cell, EPC, p42, Erk2, proliferation

scholarly journals Grb2 binding induces phosphorylation-independent activation of Shp2

2019 ◽  
Author(s):  
Chi-Chuan Lin ◽  
Lukasz Wieteska ◽  
Kin Man Suen ◽  
Arnout Kalverda ◽  
Zamal Ahmed ◽  
...  
Keyword(s):  
Mapk Pathway ◽  
Tyrosine Phosphatase ◽  
Adaptor Protein ◽  
Cancer Cell Line ◽  
Mitogen Activated Protein Kinase ◽  
Activating Mutations ◽  
Mapk Signalling ◽  
Mitogen Activated Protein ◽  
Cancer Types

AbstractThe regulation of phosphatase activity is fundamental to the control of intracellular signalling and in particular the tyrosine kinase-mediated mitogen-activated protein kinase (MAPK) pathway. Shp2 is a ubiquitously expressed protein tyrosine phosphatase and its kinase-induced hyperactivity is associated with many cancer types. In non-stimulated cells we find that binding of the adaptor protein, Grb2, in its monomeric state initiates Shp2 activity independent of phosphatase phosphorylation. Grb2 forms a bidentate interaction with both the N-terminal SH2 and the catalytic domains of Shp2, releasing the phosphatase from its auto-inhibited conformation. Grb2 typically exists as a dimer in the cytoplasm. However, its monomeric state prevails under basal conditions when it is expressed at low concentration, or when it is constitutively phosphorylated on a specific tyrosine residue (Y160). Thus, Grb2 can activate Shp2 and downstream signal transduction, in the absence of extracellular growth factor stimulation or kinase-activating mutations, in response to defined cellular conditions. We identify a polypeptide biotool capable of blocking the Grb2-Shp2 interaction. This peptide down-regulates Shp2 activity in vitro and MAPK signalling in a cancer cell line.

scholarly journals Off-target inhibition by active site-targeting SHP2 inhibitors

2018 ◽  
Author(s):  
Ryouhei Tsutsumi ◽  
Hao Ran ◽  
Benjamin G. Neel
Keyword(s):  
Growth Factor ◽  
Active Site ◽  
Tyrosine Phosphatase ◽  
Growth Factor Receptor ◽  
Sh2 Domain ◽  
Mitogen Activated Protein Kinase ◽  
Mitogen Activated Protein ◽  
Cellular Context ◽  
Site Targeting

AbstractDue to the involvement of SHP2 (SH2 domain-containing protein tyrosine phosphatase) in human disease, including Noonan syndrome and cancer, several inhibitors targeting SHP2 have been developed. Here, we report that the commonly used SHP2 inhibitor NSC-78788 does not exhibit robust inhibitory effects on growth factor-dependent MAPK (mitogen-activated protein kinase) pathway activation, and that the recently developed active site-targeting SHP2 inhibitors IIB-08, 11a-1, and GS-493 show off-target effects on ligand-evoked activation/trans-phosphorylation of the PDGFRβ (platelet-derived growth factor receptor β). GS-493 also inhibits purified human PDGFRβ and SRC in vitro, whereas PDGFRβ inhibition by IIB-08 and 11a-1 occurs only in the cellular context. Our results argue for extreme caution in inferring specific functions for SHP2 based on studies using these inhibitors.

scholarly journals Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines

2005 ◽  
Vol 12 (4) ◽  
pp. 983-998 ◽  
Author(s):  
C Festuccia ◽  
P Muzi ◽  
D Millimaggi ◽  
L Biordi ◽  
G L Gravina ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Growth Factor ◽  
Growth Inhibition ◽  
Kinase Inhibitor ◽  
Mapk Pathway ◽  
Growth Factor Receptor ◽  
Mitogen Activated Protein Kinase ◽  
Growth Modulation ◽  
Mitogen Activated Protein ◽  
Phosphoinositide 3 Kinase

To date, no effective therapeutic treatment allows abrogation of the progression of prostate cancer (PCa) to more invasive forms. One of the major targets for the therapy in PCa can be epidermal growth factor receptor (EGFR), which signals via the phosphoinositide 3′-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) pathways, among others. Despite multiple reports of overexpression in PCa, the reliance on activated EGFR and its downstream signalling to the PI3K and/or MAPK/extracellular signal-regulated kinase (ERK) pathways has not been fully elucidated. We reported that the EGFR-selective tyrosine kinase inhibitor gefitinib (ZD1839; Iressa) is able to induce growth inhibition, G1 arrest and apoptosis in PCa cells and that its effectiveness is associated primarily with phosphatase and tensin homologue deleted from chromosome 10 (PTEN) expression (and thus Akt activity). In fact PTEN-negative PCa cells are slowly sensitive to gefitinib treatment, because this molecule is unable to downregulate PI3K/Akt activity. PI3K inhibition, by LY294002 or after PTEN transfection, restores EGFR-stimulated Akt signalling and sensitizes the cells to pro-apoptotic action of gefitinib. The MAPK pathway seems to be involved primarily on cell-growth modulation because dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition (both not cell apoptosis) in PTEN-positive PCa cells and reduced EGF-mediated growth in PTEN-negative cells. Thus the effectiveness of gefitinib requires growth factor receptor-stimulated PI3K/Akt and MAPK signalling to be intact and functional. The loss of the PTEN activity leads to uncoupling of this signalling pathway, determining a partial gefitinib resistance. Moreover, gefitinib sensitivity may be maintained in these cells through its inhibitory potential in MAPK/ERK pathway activity, modulating proliferative EGFR-triggered events. Therefore, our data suggest that the inhibition of EGFR signalling can result in a significant growth reduction and in increased apoptosis in EGFR-overexpressing PCa cells with different modalities, which are regulated by PTEN status, and this may have relevance in the clinical setting of PCa.

scholarly journals Role of Ptc2 Type 2C Ser/Thr Phosphatase in Yeast High-Osmolarity Glycerol Pathway Inactivation

2002 ◽  
Vol 1 (6) ◽  
pp. 1032-1040 ◽  
Author(s):  
Christian Young ◽  
James Mapes ◽  
Jennifer Hanneman ◽  
Sheikha Al-Zarban ◽  
Irene Ota
Keyword(s):  
Catalytic Domain ◽  
Mapk Pathway ◽  
Tyrosine Phosphatase ◽  
Mitogen Activated Protein Kinase ◽  
Growth Defect ◽  
Negative Regulators ◽  
High Osmolarity ◽  
High Osmolarity Glycerol ◽  
Mitogen Activated Protein

ABSTRACT Three type 2C Ser/Thr phosphatases (PTCs) are negative regulators of the yeast Saccharomyces cerevisiae high-osmolarity glycerol mitogen-activated protein kinase (MAPK) pathway. Ptc2 and Ptc3 are 75% identical to each other and differ from Ptc1 in having a noncatalytic domain. Previously, we showed that Ptc1 inactivates the pathway by dephosphorylating the Hog1 MAPK; Ptc1 maintains low basal Hog1 activity and dephosphorylates Hog1 during adaptation. Here, we examined the function of Ptc2 and Ptc3. First, deletion of PTC2 and/or PTC3 together with PTP2, encoding the protein tyrosine phosphatase that inactivates Hog1, produced a strong growth defect at 37°C that was dependent on HOG1, providing further evidence that PTC2 and PTC3 are negative regulators. Second, overexpression of PTC2 inhibited Hog1 activation but did not affect Hog1-Tyr phosphorylation, suggesting that Ptc2 inactivates the pathway by dephosphorylating the Hog1 activation loop phosphothreonine (pThr) residue. Indeed, in vitro studies confirmed that Ptc2 was specific for Hog1-pThr. Third, deletion of both PTC2 and PTC3 led to greater Hog1 activation upon osmotic stress than was observed in wild-type strains, although no obvious change in Hog1 inactivation during adaptation was seen. These results indicate that Ptc2 and Ptc3 differ from Ptc1 in that they limit maximal Hog1 activity. The function of the Ptc2 noncatalytic domain was also examined. Deletion of this domain decreased V max by 1.6-fold and increased Km by 2-fold. Thus Ptc2 requires an additional amino acid sequence beyond the catalytic domain defined for PTCs for full activity.

Sign in / Sign up

Export Citation Format

Share Document